



NIAID Strategic Plan for Biodefense Research



NIAID Biodefense Research Agenda for CDC Category A Agents



NIAID Biodefense Research Agenda for CDC Category A Agents

Progress Report



August 2003



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens



NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

Progress Report



June 2004



January 2003



05.2005

NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats



Department of Health and Human Services
National Institutes of Health
National Institute of Allergy and Infectious Diseases
NIH Publication No. 05-5608




NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats



Biodefense Countermeasures: Key Achievements


■ Smallpox

- Dryvax; MVA; antiviral drugs




■ Anthrax

- rPA; antitoxins




■ Botulinum

- Vaccine; antitoxins



■ Ebola

- First human vaccine trials



Recent NIH Awards Using BioShield Authorities

Awards (\$29M):


- **Therapeutics for CDC Category A Agents**
- **Development and Production of Antibodies that Protect Against Botulinum Toxin Type A**
- **Production of a Vaccine Candidate Against Botulinum Toxin Type E**

Future NIH Awards Using BioShield Authorities

Future Awards:

- **Protecting the Immune System Against Radiation: BioShield Accelerated Product Development (FY 2005; \$4M)**
- **Development of Improved DTPA for Radionuclide Chelation (FY 2005; \$6M)**
- **Assays for Influenza Therapeutics (FY 2006; \$10M)**

Budgeted Milestones for Development of BioShield Priority Countermeasures



*** Previously licensed for other indications